ResMed Inc. 10-K Summary: Fiscal Year Ended June 30, 2009
Business Context and Reporting Period
This report covers the fiscal year ended June 30, 2009. ResMed Inc. is a leading developer, manufacturer, and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing (SDB), primarily obstructive sleep apnea (OSA). The company operates as a single segment, selling products in over 70 countries through wholly-owned subsidiaries and independent distributors. Key product lines include airflow generators (CPAP, VPAP, AutoSet), mask systems, and diagnostic products.
Key Financial Metrics
| Metric | Fiscal 2009 | Fiscal 2008 |
|---|---|---|
| Net Revenues | $920.7 million | $835.4 million |
| Gross Profit | $553.8 million | $493.8 million |
| Gross Margin | 60.1% | 59.1% |
| Net Income | $146.4 million | $110.3 million |
| Diluted EPS | $1.90 | $1.40 |
| Operating Cash Flow | $238.9 million | $137.8 million |
| Cash and Equivalents | $415.7 million | $321.1 million |
| Total Debt (Long-term + Current) | $161.7 million | $137.7 million |
| Working Capital | $584.2 million | $546.6 million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 10% year-over-year. Excluding unfavorable foreign currency impacts of approximately $40.3 million, organic sales growth was 15%. North and Latin America saw a 20% increase, while international sales grew 0.4% (10% organic).
- Profitability: Net income rose 33% to $146.4 million. Gross margin improved to 60% from 59%, driven by the depreciation of the Australian dollar (where manufacturing costs are denominated), favorable product mix, and supply chain efficiencies.
- Product Recall: The company recognized no additional charges for the 2007 S8 flow generator recall in fiscal 2009. The recall accrual was fully settled, with no remaining liability as of June 30, 2009.
- Restructuring: No restructuring expenses were incurred in fiscal 2009, compared to $2.4 million in fiscal 2008 related to European management streamlining.
- Share Repurchases: The company repurchased 1.83 million shares for $65.7 million. A new program authorized in May 2009 allows for the repurchase of up to 10 million additional shares.
Outlook, Risks, and Management Commentary
- Strategy: Management continues to focus on product innovation (e.g., Activa LT, Swift LT for Her), geographic expansion, and raising awareness of SDB comorbidities, particularly in cardiovascular and diabetes markets.
- Capital Allocation: Significant capital expenditures ($109.7 million) were incurred, primarily for the construction of a new corporate headquarters in San Diego ($99.9 million) and a new manufacturing facility in Singapore.
- Key Risks:
- Reimbursement: Dependence on third-party payers (Medicare, Medicaid, private insurers) creates risk of price reductions or coverage denials.
- Foreign Currency: Significant exposure to fluctuations in the Australian dollar and Euro, which impacts reported sales and earnings.
- Competition: Highly competitive market with larger rivals (e.g., Philips Respironics) and potential for new alternative treatments.
- Regulatory: Subject to strict FDA and international regulations; product recalls or compliance failures could materially harm operations.
- Liquidity of Investments: $4.3 million in auction rate securities are currently illiquid due to market conditions, though the company does not anticipate an impact on operations.
Investor Verification Checklist
- Verify the sustainability of the 60% gross margin given the volatility of the Australian dollar.
- Monitor the impact of the new 10 million share repurchase program on future earnings per share.
- Assess the timeline and success of the new Singapore manufacturing facility in reducing costs.
- Review updates on the ongoing University of Sydney intellectual property litigation.
- Track changes in Medicare reimbursement policies for Durable Medical Equipment (DME) in the U.S.
- Confirm the status of the $4.3 million auction rate securities and potential liquidity constraints.